Trametinib dimethyl sulfoxide clinical trials
Also written Mekinist.
A product of Trametinib; its studies count on that page too.
How each study uses trametinib dimethyl sulfoxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trametinib dimethyl sulfoxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 May 2013 · MEKINIST · NDA 204114 (FDA, Drugs@FDA)
- European Union
- 30 Jun 2014 · Mekinist · EMEA/H/C/002643 (EMA; as trametinib)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
National Cancer Institute (NCI) (5) · GlaxoSmithKline (1) · University Hospital, Essen (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Trametinib
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses trametinib dimethyl sulfoxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK InhibitionRecruitingPhase 2University Hospital, EssenNCT04619316Written as Trametinib 2 MG [Mekinist]
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439357Written as Trametinib Dimethyl Sulfoxide
- Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439318Written as Trametinib Dimethyl Sulfoxide
- Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439279Written as Trametinib Dimethyl Sulfoxide
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04557956Written as Trametinib Dimethyl Sulfoxide
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedPhase 2/3National Cancer Institute (NCI)NCT02101788Written as Trametinib Dimethyl Sulfoxide
- A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor MalignanciesCompletedPhase 1GlaxoSmithKlineNCT01725100Written as GSK1120212B (Standard DMSO content)
Given beside what is tested · 9 — trametinib dimethyl sulfoxide is usual care or a partner of the new treatment
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439292Written as Trametinib Dimethyl Sulfoxide
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02224781Written as Trametinib Dimethyl Sulfoxide
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02196181Written as Trametinib Dimethyl Sulfoxide
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03919071Written as Trametinib Dimethyl Sulfoxide
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04527549Written as Trametinib dimethyl sulfoxide
- Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01902173Written as Trametinib Dimethyl Sulfoxide
- Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester DiseaseCompletedPhase 2National Human Genome Research Institute (NHGRI)NCT02281760Written as Trametinib Dimethyl Sulfoxide
- Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnPhase 2National Cancer Institute (NCI)NCT03794297Written as Trametinib Dimethyl Sulfoxide
- Absolute Bioavialability of GSK1120212CompletedPhase 1GlaxoSmithKlineNCT01416337Written as GSK1120212B
Codes
What other systems call trametinib dimethyl sulfoxide · ClinicalTrials.gg INT016133
- UNII (FDA) BSB9VJ5TUTTRAMETINIB DIMETHYL SULFOXIDEConfirmed FDA, Wikidata
- RxNorm 1425098Confirmed FDA, Wikidata
- Wikidata Q27145671trametinib dimethyl sulfoxideConfirmed FDA, Wikidata
- NCI Thesaurus C152711Trametinib Dimethyl SulfoxideOne source FDA
- DrugBank DBSALT001947One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BSB9VJ5TUT | TRAMETINIB DIMETHYL SULFOXIDE | Confirmed FDA, Wikidata |
| RxNorm | 1425098 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27145671 | trametinib dimethyl sulfoxide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152711 | Trametinib Dimethyl Sulfoxide | One source FDA |
| DrugBank | DBSALT001947 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.